

NEUROSCIENTIFIC BIOPHARMACEUTICALS APPOINTS INTERNATIONAL SCIENTIFIC ADVISORS

HIGHLIGHTS

- **Highly experienced clinical ophthalmologist Dr Peter Hink appointed to Scientific Advisory Board ahead of planned Glaucoma clinical study in patients**
- **Globally recognised toxicologist Dr Frank Bonner also appointed to Scientific Advisory Board to enhance R&D capabilities and provide guidance on pivotal safety studies**

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the company**”) is pleased to announce significant additions to its Scientific Advisory Board with the appointment of highly experienced clinical ophthalmologist Dr Peter Hnik MD MHSc, and internationally recognised toxicologist and ex-pharma executive Dr Frank Bonner PhD FBTS.

Dr Hnik received his medical degree from the Medical Faculty of Charles University of Prague in 1981. After practicing for years at the Eye Clinic of the Charles University Hospital where he performed surgery and consultation in glaucoma and neuro-ophthalmology, Dr. Hnik later joined the Eye Clinic of the University of British Columbia as part of the glaucoma research group. He received his Master of Health Sciences degree from the University of British Columbia in 1999. He has authored numerous ocular publications and presentations at international forums. Based in Vancouver, Canada Dr Hnik has until recently served as a Board member and Chief Medical Officer at iCo Therapeutics Inc. and is President of Clinscape Consulting Inc. providing clinical guidance/consulting to a number of biotech companies. Dr. Hnik is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), the Drug Information Association (DIA), and the New York Academy of Sciences

Dr Bonner has over 35 years of experience in toxicology and non-clinical drug development, including as Senior Vice President of Non-Clinical Safety at global pharmaceutical company Sanofi SA. Dr Bonner has comprehensive knowledge of non-clinical safety including all aspects of regulatory guidance, outsourced programme management, mechanistic toxicology, and the application of new technologies to improve predictive screening. Based in the UK, Dr Bonner is a fellow of the British Toxicology Society, Past President of the Society, and has served as a scientific advisor for a number of internationally-based technology and drug development companies.

NeuroScientific’s Managing Director and CEO Matt Liddelow commented: *“We are extremely pleased and excited with the addition of international experts Dr Hnik and Dr Bonner to our Scientific Advisory Board. Clinical ophthalmologist Dr Hnik has been involved in ocular research for much of his career, with a specific focus in neuro-ophthalmology, and*

will provide important guidance on the design and execution of our ocular clinical studies. As a previous senior VP in R&D at global pharmaceutical company Sanofi, Dr Bonner brings to NeuroScientific invaluable knowledge and experience in relation to all aspects of R&D toxicology.”

Dr Hnik commented: *“EmtinB™ seems to be a very promising compound in preventing neurodegeneration in a number of critical conditions such as Alzheimer’s disease, multiple sclerosis and certain ocular conditions associated with optic nerve damage. I am very excited to be part of the development of this novel therapy with great potential benefit to patients with otherwise limited treatment options”.*

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+ 61 8 6382 1805

Lucas Robinson
Investor Relations
Corporate Storytime
lucas@corporatestorytime.com
+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinB™, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB™. For more information, please visit www.neuroscientific.com

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.

Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinB™ in humans.